Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 46

recruiting
3 987
countries
28
conditions
2 109

955 trials match your criteria

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:BI 685509

Colitis ulcerative

Not recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep

Neuralgia

Not recruiting

Study on the Effectiveness and Safety of NT 201 Injections for Adults with Chronic Neuropathic Pain from Postherpetic Neuralgia or Nerve Injury

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab

Dermatitis atopic

Not recruiting

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.